NovelMed Receives FDA IND Approval for NM8074 (Ruxoprubart), the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder [Yahoo...
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Up to 50% of IgAN patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis. Ruxoprubart is a highly selective inhibitor of the alternative complement pathway, which plays a critical role in the pathogenesis of IgAN. The Bb blocker is a multi-indication therapy with potential applications across a spectrum of disorders, including hemolytic, ocular, and renal diseases. Ruxoprubart is being positioned as the next-generation IgAN treatment based on its selective mechanism of action, where the drug does not block the classical pathway (CP), an important advantage over other complement blockers. Clinical data from the drug administration in naïve PNH patients shows promising results with a clean safety and efficacy profile, further supporting its potential to deliver meaningful clinical benefits. Unlike the traditional "one drug, one disease" model, Ruxoprubart has the potential to treat multiple chronic rare and common diseases. Ruxoprub
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Sandoz Boss Warns There's a Climate Cost of Obesity Wonder Drugs [Yahoo! Finance]Yahoo! Finance
- Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing [Yahoo! Finance]Yahoo! Finance
- Novartis AG (NVS): Among the Oversold Global Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- NVS vs. LLY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/29/24 - Beat
NVS
Sec Filings
- 11/25/24 - Form 6-K
- 10/29/24 - Form 6-K
- 10/29/24 - Form 6-K
- NVS's page on the SEC website